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Background: Helicobacter pylori	(H. pylori)	is	associated	with	lower	risks	of	Barrett's	
esophagus	 and	 esophageal	 adenocarcinoma,	 but	whether	H. pylori eradication in-
creases the risk of these conditions is unknown. This study aimed to test the hypoth-
esis that H. pylori	eradication	leads	to	gradually	increased	risks	of	Barrett's	esophagus	
and	esophageal	adenocarcinoma	over	 time,	while	esophageal	 squamous	cell	 carci-
noma was assessed for comparison reasons.
Material and Methods: This	Swedish	nationwide,	population-based	cohort	study	in	
2005-2012	used	data	 from	the	Swedish	Prescribed	Drug	Registry	 to	assess	eradi-
cation treatment for H. pylori.	Barrett's	esophagus	was	identified	from	the	Swedish	
Patient	Registry,	and	esophageal	adenocarcinoma	and	squamous	cell	carcinoma	from	
the	Swedish	Cancer	Registry.	Standardized	 incidence	 ratios	 (SIRs)	with	95%	confi-
dence	 intervals	 (CIs)	were	calculated	by	dividing	 the	observed	 risk	 in	 the	H. pylori 










over time after eradication treatment for H. pylori.
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1  | INTRODUC TION
The incidence of esophageal adenocarcinoma has increased mark-
edly	 in	 Western	 countries	 since	 the	 1970s.1 In most Western 
countries	(including	Sweden),	the	incidence	of	esophageal	adenocar-
cinoma	has	surpassed	that	of	esophageal	squamous	cell	carcinoma,	
which is the most common histologic type of esophageal cancer 
globally.2	For	esophageal	adenocarcinoma	and	 its	precursor	 lesion	
Barrett's	 esophagus,	 the	 main	 risk	 factors	 are	 gastroesophageal	
reflux	 disease	 (GERD)	 and	 obesity,	while	 presence	 of	Helicobacter 
pylori	 (H. pylori)	 in	 the	 stomach	 is	 associated	with	 a	 32%-56%	de-
creased	risk	of	Barrett's	esophagus,3	and	a	36%-44%	decreased	risk	
of esophageal adenocarcinoma.3 These inverse associations with 
H. pylori are thought to be the result of H. pylori-associated	gastric	
atrophy,	which	leads	to	lower	gastric	acid	production	and	thus	lower	
prevalence	of	GERD.	Yet,	 it	 is	not	studied	 if	eradication	treatment	
for H. pylori	increases	the	risks	of	Barrett's	esophagus	or	esophageal	
adenocarcinoma. H. pylori	 infection	is	otherwise	a	well-established	
risk	factor	of	noncardia	gastric	adenocarcinoma,	and	its	eradication	




To test the hypothesis that H. pylori eradication increases the 
risks	of	Barrett's	 esophagus	 and	esophageal	 adenocarcinoma,	 and	
does	not	influence	the	risk	of	esophageal	squamous	cell	carcinoma,	
we conducted a nationwide Swedish cohort study.
2  | MATERIAL AND METHODS
2.1 | Design
This	population-based	and	nationwide	Swedish	cohort	study	included	
patients aged 18 years and older who had eradication treatment for 
H. pylori	during	the	study	period	July	1,	2005,	to	December	31,	2012.	
The source cohort has been described in detail previously.5,7	For	the	
purpose	 of	 the	 present	 study,	 the	 risk	 of	 Barrett's	 esophagus,	 es-
ophageal	adenocarcinoma,	and	esophageal	squamous	cell	carcinoma	
among the cohort participants was compared to the risk in the cor-
responding Swedish background population. The data were retrieved 
from	well-maintained	nationwide	Swedish	registers	that	were	linked	
for	each	study	participant	by	their	unique	personal	identity	number	
assigned to all residents in Sweden at birth or immigration. The study 
was approved by the Regional Ethical Review Board in Stockholm 
(2014/1291-31/4),	and	the	need	for	informed	consent	was	waived.
2.2 | Exposure
The study exposure was eradication treatment for H. pylori using 
a	 proton-pump	 inhibitor	 (PPI)	 in	 combination	with	 at	 least	 two	 of	
the	 antibiotics	 clarithromycin,	 amoxicillin,	 or	 metronidazole,	 as	
described earlier.7 The data on eradication treatment were re-
trieved	 from	 the	Swedish	Prescribed	Drug	Registry,	which	 started	
on	July	1,	2005,	and	contains	information	on	all	prescribed	and	dis-
pensed	medications	 that	 are	 used	outside	 in-hospital	 care	 for	 the	
whole Swedish population.8	The	medications	(with	their	Anatomical	
Therapeutic	Chemical	codes)	representing	H. pylori eradication were 
a combination package used for H. pylori eradication containing the 
PPI esomeprazole and the antibiotics clarithromycin and amoxicil-
lin	 (A02BD06),	 and	 prescriptions	 of	 a	 PPI	 (A02BC)	 together	 with	
clarithromycin	 (J01FA09),	 amoxicillin	 (J01CA04),	 or	metronidazole	
(J01XD01).	The	separate	prescriptions	had	 to	 include	at	 least	 two	
antibiotics	 that	were	prescribed	on	 the	 same	date,	 and	a	PPI	pre-
scribed	within	a	window	of	60	days	before	to	5	days	after	the	anti-
biotics. This was done in order to include individuals already using a 
PPI and to take nonavailability in the pharmacy into account.
2.3 | Outcomes
The	 main	 outcome	 was	 Barrett's	 esophagus,	 and	 the	 secondary	
outcome	 was	 esophageal	 adenocarcinoma.	 Esophageal	 squamous	
cell carcinoma was examined only for comparison reasons. New 
diagnoses	of	Barrett's	esophagus	were	assessed	from	the	Swedish	
Patient Registry using the International Classification of Diseases 10 
(ICD10)	code	K22.7	that	was	available	from	2006	onwards.9 Newly 
detected esophageal cancers were assessed from the Swedish 
Cancer	Registry	using	the	ICD7	codes	150,	150.0,	150.8,	and	150.9.	




tection of the outcomes due to examinations preceding the eradica-
tion	 treatment.	Therefore,	 the	 start	 of	 follow-up	was	1	 year	 after	
H. pylori	eradication	treatment	for	all	participants.	In	each	individual,	
only	the	first	ever	cancer	episode	was	considered.	Thus,	participants	
were eligible only if they had no history of cancer.
2.4 | Statistical analysis
Standardized	 incidence	 ratios	 (SIRs)	 were	 calculated	 by	 dividing	
the observed number of cases in the H. pylori eradication cohort by 
the expected number of cases in the corresponding Swedish back-
ground population.10 Standardization was performed on the vari-
ables	age	group	(18-59,	60-69,	and	≥70	years),	sex	(men	and	women),	
and	 calendar	 period	 (2005-2006,	 2007-2009,	 and	 2010-2012).	 To	
calculate	the	number	of	person-years	of	follow-up	in	each	stratum,	
Clayton's	algorithm	was	used,	where	follow-up	started	from	1	year	
after the date of the first dispensed prescription for eradication 
of H. pylori.11	An	 additional	 analysis	 instead	 counted	person-years	
starting from the date of the last dispensed prescription for H. py-
lori	eradication.	Follow-up	discontinued	at	the	date	of	occurrence	of	
any	cancer,	death,	or	end	of	the	study	period	(December	31,	2012),	
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whichever	 came	 first.	For	 the	analysis	of	Barrett's	esophagus,	 the	
first	date	of	Barrett's	diagnosis	was	added	to	the	end	of	follow-up	
criteria.	Barrett's	diagnoses	in	the	first	year	after	eradication	treat-
ment were removed from the analysis and the entire cohort started 
1 year after eradication.
Subgroup analyses were performed to assess the risk of the 
outcomes	 over	 time	 after	 eradication	 treatment	 (categorized	 into	
1-2,	3-4,	or	5-7.5	years)	and	number	of	eradication	treatments	(1,	2,	
or	≥	3).	Multiple	eradication	treatments	indicated	that	H. pylori was 
present for a prolonged amount of time.
The	statistical	software	STATA	(Stata	Corp	v.	13.0)	was	used	for	
all data management and analyses.
3  | RESULTS
3.1 | Participants
The study cohort included 81 919 individuals with at least one dis-
pensed prescription for H. pylori eradication treatment during the 
study	 period.	 Of	 these	 participants,	 53.9%	 were	 women,	 60.9%	
were	59	years	of	age	or	younger,	and	74.8%	resided	in	urban	areas	
(Table	1).	The	study	cohort	for	Barrett's	esophagus	included	slightly	
fewer	cohort	participants	 (n	=	81	669)	because	 individuals	 receiv-
ing	Barrett's	esophagus	diagnosis	before	the	eradication	treatment	
were	excluded.	During	the	follow-up	(mean	3.2	years)	from	1	year	
after	 eradication	 treatment,	 178	 (0.22%)	 participants	 had	 a	 new	
Barrett's	 esophagus	 diagnosis,	 11	 (0.01%)	 developed	 esophageal	
adenocarcinoma,	and	10	(0.01%)	had	an	esophageal	squamous	cell	
carcinoma diagnosis.
3.2 | Helicobacter pylori eradication treatment and 
risk of Barrett's esophagus
For	Barrett's	 esophagus,	 the	 overall	 SIR	was	 increased	 (3.67,	 95%	
CI	3.15-4.25),	but	the	SIRs	did	not	increase	over	time	after	eradica-
tion	treatment,	but	rather	decreased,	from	4.32	(95%	CI	3.53-5.23)	
at	 1-2	 years-3.09	 (95%	CI	 1.98-4.59)	 at	 5-7.5	 years	 after	 eradica-
tion	(Table	2).	Analysis	from	the	date	of	 last	eradication	treatment	
showed a similar trend apart from the analysis by number of eradi-
cations	(Table	3).	There	was	no	clear	trend	in	risk	depending	on	the	
number	of	eradication	episodes	 (Table	2),	and	there	were	no	clear	
differences	 in	 risk	 between	 the	 sexes	 (Table	 4).	 Individuals	 aged	
59	years	or	younger	had	a	higher	SIR	of	Barrett's	esophagus	than	the	
oldest	age	group	at	any	follow-up	time	(Table	4).
3.3 | Helicobacter pylori eradication treatment and 
risk of esophageal adenocarcinoma
The overall SIR of esophageal adenocarcinoma was slightly increased 
after H. pylori eradication treatment although not statistically 
significant	 (SIR	 1.26,	 95%	 CI	 0.62-2.26).	 The	 point	 estimates	 de-
creased	 after	 eradication	 treatment	 from	1.36	 (95%	CI	 0.50-2.97)	
1-2	years	to	0.73	 (95%	CI	0.01-4.08)	5-7.5	years	 (Table	2).	Ten	out	
of 11 cases of esophageal adenocarcinoma were detected in par-
ticipants	 with	 1	 prescribed	 eradication	 treatment	 (SIR	 1.28,	 95%	
CI	0.61-2.36).	Analysis	 from	the	date	of	 last	eradication	 treatment	
showed	similar	findings	(Table	3).
3.4 | Helicobacter pylori eradication treatment and 
risk of esophageal squamous cell carcinoma
The	overall	SIR	of	esophageal	squamous	cell	carcinoma	was	slightly	




TA B L E  1   Characteristics of study participants at time of 
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4  | DISCUSSION
This study provided no support for the hypothesis of a gradually in-
creased	risk	of	Barrett's	esophagus	or	esophageal	adenocarcinoma	
over time after eradication treatment for H. pylori, and no clear as-
sociation	was	found	with	esophageal	squamous	cell	carcinoma.
Strengths	of	this	study	were	the	population-based	design	which	
counteracts	 selection	 bias,	 the	 large	 cohort	 size	 with	 many	 per-
son-years	at	 risk,	 the	data	 retrieved	 from	well-maintained	and	na-
tional	registers,	and	the	complete	follow-up.	A	major	limitation	was	
the	low	number	of	cases	of	esophageal	adenocarcinoma	(and	esoph-
ageal	squamous	cell	carcinoma),	why	 the	 results	 for	 these	cancers	









Another	 weakness	 was	 the	 limited	 follow-up	 time	 (maximum	
of	7.5	years).	Thus,	longer-term	associations	could	not	be	assessed.	
Although	these	results	may	be	indicative	for	the	risk	of	esophageal	




Another	 limitation	 was	 exposure	 misclassification	 for	 vari-
ous	 reasons.	 First,	 the	 registers	 did	 not	 have	 information	 on	 the	
success	 of	 the	 eradication	 treatment,	 which	 means	 that	H. pylori 
might	have	remained	after	treatment	in	some	participants.	Second,	
the background population consists of both H. pylori-positive	 and	
H. pylori-negative	 individuals	 (H. pylori prevalence in Sweden is 
TA B L E  2  Standardized	incidence	ratios	(SIRs)	with	95%	confidence	intervals	(CIs)	of	Barrett's	esophagus,	esophageal	adenocarcinoma	
and	esophageal	squamous	cell	carcinoma	after	Helicobacter pylori	eradication	treatment	in	Sweden	in	2005-2012
 
Barrett's esophagus Esophageal adenocarcinoma
Esophageal squamous cell 
carcinoma
Number SIR (95% CI) Number SIR (95% CI) Number SIR (95% CI)
Total 178 3.67	(3.15-4.25) 11 1.26	(0.62-2.26) 10 1.63	(0.78-3.01)
Follow-up	time,	years
1-2 104 4.32	(3.53-5.23) 6 1.36	(0.50-2.97) 5 1.59	(0.51-3.70)
3-4 50 3.00	(2.23-3.95) 4 1.35	(0.36-3.47) 5 2.45	(0.79-5.72)
5-7.5 24 3.09	(1.98-4.59) 1 0.73	(0.01-4.08) 0 NA
Number of eradications
1 141 3.27	(2.75-3.85) 10 1.28	(0.61-2.36) 9 1.15	(0.52-2.19)
2 30 7.31	(4.93-10.44) 1 1.42	(0.02-7.92) 0 NA
≥3 7 5.44	(2.18-11.21) 0 NA 1 4.71	(0.07-26.21)
Abbreviation:	NA,	not	applicable
TA B L E  3  Standardized	incidence	ratios	(SIRs)	with	95%	confidence	intervals	(CIs)	of	Barrett's	esophagus,	esophageal	adenocarcinoma,	
and	esophageal	squamous	cell	carcinoma	after	the	last	Helicobacter pylori	eradication	treatment	in	Sweden	in	2005-2012
 
Barrett's esophagus Esophageal adenocarcinoma
Esophageal squamous cell 
carcinoma
Number SIR (95% CI) Number SIR (95% CI) Number SIR (95% CI)
Total 153 3.33	(2.82-3.90) 11 1.28	(0.64-2.29) 9 1.52	(0.62-2.88)
Follow-up	time,	years
1-2 86 3.70	(2.96-4.57) 6 1.41	(0.52-3.07) 4 1.32	(0.35-3.40)
3-4 44 2.81	(2.04-3.77) 4 1.44	(0.39-3.68) 5 2.61	(0.84-6.09)
5-7.5 23 3.27	(2.07-4.91) 1 0.81	(0.01-4.45) 0 NA
Number of eradications
1 141 3.07	(2.58-3.62) 10 1.28	(0.61-2.36) 9 1.15	(0.52-2.19)
2 10 2.44	(1.17-14.48) 1 2.45	(0.03-13.91) 0 NA
≥3 2 1.55	(0.18-5.61) 0 NA 0 NA
Abbreviation:	NA,	not	applicable
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amined the association between eradication treatment for H. pylori 
and	 the	 risk	 of	 Barrett's	 esophagus,	 esophageal	 adenocarcinoma,	
and	 esophageal	 squamous	 cell	 carcinoma.	 The	 lack	 of	 increased	
risk estimates over time after eradication treatment during a pe-
riod	of	7.5	years	argues	against	the	hypothesis	of	an	increased	risk	
of	 Barrett's	 esophagus	 and	 esophageal	 adenocarcinoma	 following	
eradication	 treatment.	A	possible	explanation	 for	 these	 findings	 is	
that gastric atrophy caused by infection with H. pylori might not be 
reversible by means of eradication treatment. Gastric atrophy leads 
to reduced or absent secretion of gastric acid and thus a reduction 
in	acidic	gastroesophageal	 reflux,	which	 is	 the	main	 risk	 factor	 for	
Barrett's	esophagus	and	esophageal	adenocarcinoma.
Although	several	 studies	suggested	 that	H.	pylori	 is	protective	
against	 esophageal	 cancer,	 a	 recent	meta-analysis	 did	 not	 provide	
strong and consistent evidence for this hypothesis.13	Although	most	
sub-analyses	in	that	meta-analysis	suggested	lower	risks	compared	
to	the	comparison	groups	in	the	individual	studies,	methodological	
heterogeneity was high and there were important variations based 
on	study	characteristics	(including	etno-geographical	differences).13 
Our	study	uses	the	entire	Swedish	population	as	a	comparison	group,	
and we have excluded the first year after eradication to reduce the 
risk	of	reverse	causality	(ie,	individuals	being	diagnosed	and	treated	
for	early	signs	of	yet	undiagnosed	cancer).	Yet,	 individuals	who	re-
ceived eradication treatment may also be followed up more closely 
leading	to	earlier	detection,	and	therefore	creating	a	risk	of	detec-
tion	bias;	 and	 residual	 confounding	 (beyond	age,	 sex,	 time	period)	
cannot be ruled out. These elements may contribute to the apparent 
higher	risk	of	Barrett's	esophagus	and	esophageal	adenocarcinoma	
compared	to	the	Swedish	background	population,	even	in	the	time	
period closest to the eradication treatment when lower risks may 
have been expected.
The results of this study do not give any reason to hold back 
on eradication in individuals who have an indication to receive this 
treatment,	despite	being	at	an	 increased	risk	of	developing	esoph-
ageal	 adenocarcinoma.	 However,	 further	 and	 larger	 studies	 with	
longer	follow-up	are	needed	on	this	topic,	including	studies	from	dif-
ferent regions representing high and low prevalence areas of H. py-
lori and high and low incidence areas of esophageal adenocarcinoma.
5  | CONCLUSION
To	conclude,	this	first	study	assessing	the	risk	of	Barrett's	esopha-
gus and esophageal adenocarcinoma after eradication treatment for 
H. pylori did not show any gradually increased risk over time after 
treatment. These findings do not provide any strong evidence to re-
frain from H. pylori	eradication	whenever	indicated,	even	in	individu-
als at increased risk of esophageal adenocarcinoma.
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1-2 y 3-4 y 5-7.5 y
Patients (number) SIR (95% CI) Patients (number) SIR (95% CI) Patients (number) SIR (95% CI)
Total 104 4.32	(3.53-5.23) 50 3.00	(2.23-3.95) 24 3.09	(1.98-4.59)
Sex
Men 63 3.93	(3.02-5.03) 34 3.10	(2.14-4.33) 14 2.76	(1.51-4.63)
Women 41 5.08	(3.65-6.89) 16 2.81	(1.61-4.56) 10 3.71	(1.78-6.82)
Age,	years
18-59 38 7.62	(5.39-10.46) 11 3.55	(1.77-6.36) 6 4.60	(1.68-10.01)
60-69 33 3.76	(2.59-5.28) 26 4.29	(2.80-6.28) 8 2.81	(1.21-5.53)
≥70 33 3.20	(2.20-4.49) 13 1.73	(0.92-2.96) 10 2.76	(1.32-5.08)
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